Dr. Hellmann on Using Trametinib in Low-Grade Ovarian Serous Carcinoma

Partner | Cancer Centers | <b>John Theurer Cancer Center</b>

Mira Hellmann, MD, discusses using trametinib to treat patients with low-grade ovarian serous carcinomas.

Mira Hellmann, MD, gynecologic oncologist and assistant professor, Hackensack Meridian John Theurer Cancer Center at Hackensack University Medical Center, discusses using trametinib (Mekinist) to treat patients with low-grade ovarian serous carcinomas.

Patients with low-grade ovarian serous carcinomas are difficult to treat because they are often chemotherapy-resistant and are usually treated with hormonal therapy or sometimes chemotherapy with little yield, explains Hellmann.

The GOG-0281 trial examined patients with low-grade serous tumors and compared treatment with hormonal therapy versus chemotherapy versus the MEK inhibitor trametinib. The trametinib arm showed an improvement in progression-free survival, giving this patient population a new treatment option, concludes Hellmann.